Surrozen, Inc. (SRZNW)South San Francisco, United States | NasdaqCM
0.00 USD
+0.00
(153.333%)
⇧
(Aug. 6, 2026, 10:43 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:42 a.m. EDT
The security is effectively worthless and devoid of investment merit. Fundamentally, the company reports negative gross and operating margins, negative free cash flow, and a negative book value, indicating a business that is destroying capital rather than generating value. The price history confirms this collapse, showing the stock trading at zero for the last two weeks and hitting a fifty-two-week low of $0.0015, which suggests a delisting or complete loss of liquidity. There is no dividend to speak of, and the lack of analyst recommendations combined with stagnant trading volume indicates the market has abandoned the asset entirely. Any recent news of a 'surge' appears to be noise on an asset with no floor, making this a clear avoid. |
| Attribute | Value |
|---|---|
| Revenue per Share | 1.142 |
| Beta | 0.56 |
| Previous Name | Consonance-HFW Acquisition Corp. |
| Website | https://www.surrozen.com |
| Attribute | Value |
|---|---|
| Address1 | 171 Oyster Point Boulevard |
| Address2 | Suite 400 |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | 0.559 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | -18.603 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0038 |
| Current Ratio | 12.141 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0015 |
| Day Low | 0.0015 |
| Earnings Quarterly Growth | 0.262 |
| Ebitda | -44,128,000 |
| Ebitda Margins | 0.0 |
| Eps Trailing Twelve Months | -5.695 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0015 |
| Fifty Two Week High Change | 0.0023 |
| Fifty Two Week High Change Percent | 1.5333333 |
| Fifty Two Week Low | 0.0015 |
| Fifty Two Week Low Change | 0.0023 |
| Fifty Two Week Low Change Percent | 1.5333333 |
| Fifty Two Week Range | 0.0015 - 0.0015 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 4,617,855 |
| Free Cashflow | -21,751,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 44 |
| Fullday Change | 0.0023 |
| Fullday Change Percent | 153.33333 |
| Fullday Price | 0.0038 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -2.00382 |
| Gross Profits | -23,066,000 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,021-08-12 |
| Language | en-US |
| Long Business Summary | Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California. |
| Long Name | Surrozen, Inc. |
| Market | us_market |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_401948183 |
| Name Change Date | 2,026-10-15 |
| Net Income To Common | -324,564,000 |
| Open | 0.009 |
| Operating Cashflow | -34,762,000 |
| Operating Margins | -2.074 |
| Phone | 650 489 9000 |
| Prev Name | Consonance-HFW Acquisition Corp. |
| Previous Close | 0.0015 |
| Price Hint | 4 |
| Price To Book | -0.00020426813 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.879 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0023 |
| Regular Market Change Percent | 153.33333 |
| Regular Market Day High | 0.0015 |
| Regular Market Day Low | 0.0015 |
| Regular Market Day Range | 0.0015 - 0.0015 |
| Regular Market Open | 0.009 |
| Regular Market Previous Close | 0.0015 |
| Regular Market Price | 0.0038 |
| Regular Market Time | 1,786,027,433 |
| Regular Market Volume | 26,468 |
| Return On Assets | -0.25395 |
| Revenue Growth | 4.086 |
| Revenue Per Share | 1.142 |
| Sand P52 Week Change | 0.16440773 |
| Sector | |
| Sector Key | |
| Short Name | Surrozen, Inc. Warrant |
| Source Interval | 15 |
| State | CA |
| Symbol | SRZNW |
| Total Cash | 102,039,000 |
| Total Cash Per Share | 8.682 |
| Total Debt | 6,316,000 |
| Total Revenue | 11,511,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.695 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 26,468 |
| Website | https://www.surrozen.com |
| Zip | 94,080 |